Sugi Predict

Sugi Predict / Compounds / Droxinavir

Droxinavir

Droxinavir

SCHEMBL668266

CNCC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@H](O)CN(CCC(C)C)C(=O)NC(C)(C)C)C(C)(C)C

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PSEN1 P49768 11/20 0.42
▸ PSEN2 P49810 11/20 0.42
▸ APH1B Q8WW43 11/20 0.42
▸ NCSTN Q92542 11/20 0.42
▸ APH1A Q96BI3 11/20 0.42
▸ PSENEN Q9NZ42 11/20 0.42
▸ MMP2 P08253 4/20 0.41
▸ MMP3 P08254 2/20 0.41
▸ CTSD P07339 1/20 0.41
▸ MLNR O43193 1/20 0.41
▸ NR1I2 O75469 1/20 0.41
▸ SLCO2B1 O94956 1/20 0.41
▸ ABCB11 O95342 1/20 0.41
▸ ABCB1 P08183 1/20 0.41
▸ UGT1A1 P22309 1/20 0.41
▸ CCKAR P32238 1/20 0.41
▸ OPRK1 P41145 1/20 0.41
▸ GHSR Q92847 1/20 0.41
▸ SLCO1B3 Q9NPD5 1/20 0.41
▸ ABCG2 Q9UNQ0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Droxinavir SCHEMBL8170296 1.00 PSEN1 (0.42) PSEN1PSEN2APH1BNCSTNAPH1A
Droxinavir SCHEMBL668267 1.00 PSEN1 (0.42) PSEN1PSEN2APH1BNCSTNAPH1A
Droxinavir SCHEMBL12510780 1.00 PSEN1 (0.42) PSEN1PSEN2APH1BNCSTNAPH1A
Droxinavir SCHEMBL14613663 1.00 PSEN1 (0.42) PSEN1PSEN2APH1BNCSTNAPH1A
Droxinavir SCHEMBL14044444 1.00 PSEN1 (0.42) PSEN1PSEN2APH1BNCSTNAPH1A
Droxinavir SCHEMBL29636917 0.99 PSEN1 (0.42) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL8602994 0.92 PSEN1 (0.39) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL7402349 0.91 PSEN1 (0.48) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6227028 0.89 PSEN1 (0.44) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL8570558 0.89 PSEN1 (0.44) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2961730-A2 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XenoPort, Inc. (US) 2016-01-06 — — EP claimed
US-20150158809-A9 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2015-06-11 — — US claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
EP-2846788-A1 USE OF COMPOUNDS FOR THE TREATMENT OF PAIN Akron Molecules AG (AT) 2015-03-18 — — EP claimed
WO-2014134005-A2 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2014-09-04 — — WO claimed
US-20140243544-A1 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2014-08-28 — — US claimed
CN-101486668-B Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof XENOPORT INC 2014-07-02 — — CN claimed
WO-2013167743-A1 USE OF COMPOUNDS FOR THE TREATMENT OF PAIN AKRON MOLECULES GMBH (AT) 2013-11-14 — — WO claimed
US-8299291-B2 Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs XENOPORT, INC. (US) 2012-10-30 — — US claimed
US-8062870-B2 Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs XENOPORT, INC. (US) 2011-11-22 — — US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 — — CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 — — EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US claimed
WO-2003085127-A2 METHOD FOR IDENTIFICATION OF INSULIN RECEPTOR KINASE ACTIVATORS TELIK, INC. (US) 2003-10-16 — — WO claimed
US-6528037-B2 Via administering HIV protease inhibitor and glucose to rats and measuring the increases in plasma TELIK, INC. 2003-03-04 — — US claimed
US-20020151542-A1 Method for determining whether a compound is an insulin receptor kinase activator TELIK, INC. 2002-10-17 — — US claimed
EP-2841109-B1 PRODRUGS OF HYDROXYL-COMPRISING DRUGS ASCENDIS PHARMA AS (DK) 2026-04-15 — — EP disclosed
US-20020151542-A1 Method for determining whether a compound is an insulin receptor kinase activator TELIK, INC. 2002-10-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150158809-A9 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS CPS1, CA7, NAAA PSEN1 2833/4885PSEN2 3258/4885APH1B 249/4885
US-20020151542-A1 Method for determining whether a compound is an insulin receptor kinase activator INSR, GPR119, IRS1 PSEN1 3322/4885PSEN2 2643/4885APH1B 2659/4885
US-20140243544-A1 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS CPS1, CA7, NAAA PSEN1 2833/4885PSEN2 3258/4885APH1B 249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.